AL.com reports Howard Jacob is leaving the HudsonAlpha Institute for Biotechnology after three years there.
Regeneron Pharmaceuticals and its collaborators plan to sequence the exomes all of the UK Biobank participants by then end of 2019.
By the end of 2019, Regeneron plans sequence the exomes of all 500,000 participants in the UK Biobank.
The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.
The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.
The team found that cancer-causing genes depend on the BTK gene, which they believe they can shut down with an existing drug.
The partners will use population genomics to discover and develop novel therapeutics and companion diagnostics for a range of chronic diseases.
Progression-free and overall survival seen in the veliparib arm weren't statistically significant, but were encouraging enough to move the drug to Phase III, AbbVie said.
The companion test will let doctors identify the best treatment for CLL patients with 17p deletions, a subset that has historically lacked therapeutic options.
The company will use Myriad's myChoice HRD companion diagnostic to identify lung cancer patients who would be likely to respond to the drug.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.